Imatinib as a potentially effective therapeutic alternative in corticosteroid-resistant eosinophilic fasciitis.

Abstract

Eosinophilic fasciitis (EF) is a rare condition in children that is typically treated with systemic corticosteroids. We present the case of a 9-year-old boy with biopsy-proven EF, refractory to systemic corticosteroids and methotrexate. The tyrosine kinase inhibitor imatinib was added as adjuvant therapy, leading to improvement in joint function and skin laxity. Our case is the first to suggest the anti-fibrotic properties of imatinib may benefit EF patients.

• Authors: Tiffany T Wu, Heidi Goodarzi, Jennifer Wang, Roberto Novoa, Joyce M C Teng
• Journal: Pediatric dermatology (Pediatr Dermatol) Vol. 37 Issue 6 Pg. 1171-1172 (Nov 2020) ISSN: 1525-1470 [Electronic] United States
• PMID: 32970342 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2020 Wiley Periodicals LLC.

Chemical References

• Adrenal Cortex Hormones
• Imatinib Mesylate

Topics

• Adrenal Cortex Hormones
• Child
• Eosinophilia (drug therapy)
• Fasciitis (diagnosis, drug therapy)
• Humans
• Imatinib Mesylate (therapeutic use)
• Male